Q32 Bio (QTTB)

• Market cap: $43.7M
• 1 day: 7.49%
• 5 days: -3.75%
• 1 month: -86.84%
• 3 months: -92.67%
• 6 months: -77.60%
• Year to date: -78.44%
• 1 year: -78.44%
• 5 years: -78.44%
• 10 years: -78.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Employees: 42

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 9

181% more capital invested

Capital invested by funds: $144M [Q2] → $406M (+$262M) [Q3]

125% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 8

33% more funds holding

Funds holding: 54 [Q2] → 72 (+18) [Q3]

7.92% more ownership

Funds ownership: 67.61% [Q2] → 75.53% (+7.92%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 151% upside
• Avg. target: $18.17 406% upside
• High target: $22 513% upside

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	513% upside $22	Outperform Maintained	12 Dec 2024
Oppenheimer Jay Olson 20% 1-year accuracy 20 / 102 met price target	457% upside $20	Outperform Maintained	11 Dec 2024
Piper Sandler Christopher Raymond 19% 1-year accuracy 5 / 27 met price target	457% upside $20	Overweight Maintained	11 Dec 2024
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target	346% upside $16	Equal-Weight Downgraded	11 Dec 2024
Leerink Partners Thomas Smith 20% 1-year accuracy 1 / 5 met price target	151% upside $9	Market Perform Downgraded	11 Dec 2024